FDA rejects Singulair-Claritin combination

April 30, 2008

The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.

The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.

The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.

The companies did not explain the FDA's reason for rejecting the drug combo.

Copyright 2008 by United Press International

Explore further: Review article examines sublingual immunotherapy for treatment of allergic rhinitis and asthma

Related Stories

No link found between asthma drugs, suicide attempts

July 4, 2012

(Medical Xpress) -- Treating asthma with leukotriene-modifying agents does not pose an increased risk of suicide in children, according to new research at the University of Illinois at Chicago College of Pharmacy.

Drug therapy for allergy moves forward

May 12, 2014

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has ...

Recommended for you

Overcoming Opioids: When pills are a hospital's last resort

May 2, 2017

A car crash shattered Stuart Anders' thigh, leaving pieces of bone sticking through his skin. Yet Anders begged emergency room doctors not to give him powerful opioid painkillers—he'd been addicted once before and panicked ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.